FDA grants TiGenix therapy orphan drug designation & more — 5 GI company key notes

Here are five updates on GI companies from the past week:

The FDA granted TiGenix orphan drug designation for Cx601, its lead candidate which treats fistulizing Crohn's disease.

Apollo Endosurgery entered into a registry funding agreement with the American Gastroenterological Association to develop a flexible endoscopic procedures registry.

Ambu acquired Invendo Medical and its single-use endoscope business for €225 million ($265 million.)

The UK Medicines and Healthcare Products Regulatory Agency approved Norgine B.V.'s bowel cleaning solution Plenvu.

More articles on gastroenterology:
GI leader to know: Dr. Umaprasanna Karnam of Gut Whisperer Center for Digestive Health
Stock market week-in-review for 5 large GI companies — Oct. 16-20
To prevent injury, gastroenterologists should complete more ergonomics training, take breaks

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers